Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Globus Medical GMED

Globus Medical scores good on business quality (7.5 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$74.65Oct 9, 2026
Business qualityGood
Next earningsNov 4, 2026
Insiders, 90 daysSelling

Why it matters

  1. What Globus Medical does

    Globus Medical designs and sells musculoskeletal implants and surgical instruments to hospitals and surgeons. It generates revenue by providing robotic navigation systems and spinal hardware that medical professionals use during complex operations.

  2. What it does best

    Globus delivers exceptional gross margins of 68.5% compared to GEHC at 39.5%, driven by proprietary technology and specialized surgical instrumentation that hospitals struggle to substitute without retraining surgical staff.

  3. The main risk

    With no recent specific operational threats listed in the news headlines, the company remains exposed to broader hospital capital budget tightening that could delay high-value robotic system purchases.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin sits at 21.4% with a net margin of 17.0%, supported by high gross margins that indicate strong earnings conversion as sales volume scales.

MoatFair

The moat rests on high switching costs for hospitals embedded in its surgical ecosystem, supported by a gross margin ranking in the top quartile at the 62nd sector percentile.

GrowthFast

Revenue growth hit 16.7% in the latest period, accelerating past historical annual figures where revenue stood at $1.0B in 2022 and $2.5B in 2024, driven by core product adoption.

Financial healthStrong

Debt is virtually non-existent with a debt-to-equity ratio of nearly zero and interest coverage exceeding 13,000x, while free cash flow reached $750 million, making the balance sheet exceptionally strong.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

2 sold $4.4M outside pre-planned sales.

Our sealed record on GMED

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is GMED a good business?

Globus Medical scores good on the Cluenex quality check (7.5 of 10), measured against its own industry. Profitability is fair, moat fair, growth fast and financial health strong.

Are insiders buying GMED?

In the last 90 days of SEC Form 4 filings: 2 sold $4.4M outside pre-planned sales.

When does GMED report earnings?

Nov 4, 2026.

For members

See GMED today

  • Today's verdict on GMED, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Globus Medical (GMED)”, https://cluenex.com/stocks/gmed/, data as of Oct 10, 2026.